Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Alan Forrest

Showing results (71-80 of 177) with videos related to

Pageof 18
Sort By:
Antimicrobial Agents and Chemotherapy|May 30, 2013
Synergistic activity of colistin and rifampin combination against multidrug-resistant Acinetobacter baumannii in an in vitro pharmacokinetic/pharmacodynamic modelHee Ji Lee, Phillip J Bergen, Jurgen B Bulitta, et al.
International Journal of Antimicrobial Agents|October 30, 2016
Pharmacokinetics/pharmacodynamics of colistin and polymyxin B: are we there yet?Thien B Tran, Tony Velkov, Roger L Nation, et al.
Journal of Clinical Pharmacology|November 10, 2018
Definition and Validation of a Novel Metric of Erythropoiesis-Stimulating Agent Response in Hemodialysis PatientsCalvin J Meaney, Spinel Karas, Ben Robinson, et al.
Antimicrobial Agents and Chemotherapy|July 15, 2009
Pharmacodynamics of vancomycin at simulated epithelial lining fluid concentrations against methicillin-resistant Staphylococcus aureus (MRSA): implications for dosing in MRSA pneumoniaYoriko Harigaya, Jürgen B Bulitta, Alan Forrest, et al.
Current Pharmaceutical Biotechnology|May 11, 2011
Relevance of pharmacokinetic and pharmacodynamic modeling to clinical care of critically ill patientsJurgen B Bulitta, Cornelia B Landersdorfer, Alan Forrest, et al.
Biopharmaceutics & Drug Disposition|November 29, 2007
Pharmacokinetic interaction between efavirenz and dual protease inhibitors in healthy volunteersQing Ma, Alan Forrest, Susan L Rosenkranz, et al.
The Journal of Antimicrobial Chemotherapy|November 29, 2007
Microbiological effects of prior vancomycin use in patients with methicillin-resistant Staphylococcus aureus bacteraemiaPamela A Moise, Davida S Smyth, Nadia El-Fawal, et al.
Antimicrobial Agents and Chemotherapy|August 1, 2018
Population Pharmacokinetic Analyses for Ertapenem in Subjects with a Wide Range of Body SizesElizabeth A Lakota, Cornelia B Landersdorfer, Li Zhang, et al.
Expert Opinion on Drug Metabolism & Toxicology|May 7, 2013
Considering CYP1A2 phenotype and genotype for optimizing the dose of olanzapine in the management of schizophreniaVidya Perera, Annette S Gross, Thomas M Polasek, et al.
Scientific Reports|March 31, 2017
Untargeted metabolomics analysis reveals key pathways responsible for the synergistic killing of colistin and doripenem combination against Acinetobacter baumanniiMohd Hafidz Mahamad Maifiah, Darren J Creek, Roger L Nation, et al.
Pageof 18

Showing results (71-80 of 177) with videos related to

Sort By:
Pageof 18
Antimicrobial Agents and Chemotherapy|May 30, 2013
Synergistic activity of colistin and rifampin combination against multidrug-resistant Acinetobacter baumannii in an in vitro pharmacokinetic/pharmacodynamic modelHee Ji Lee, Phillip J Bergen, Jurgen B Bulitta, et al.
International Journal of Antimicrobial Agents|October 30, 2016
Pharmacokinetics/pharmacodynamics of colistin and polymyxin B: are we there yet?Thien B Tran, Tony Velkov, Roger L Nation, et al.
Journal of Clinical Pharmacology|November 10, 2018
Definition and Validation of a Novel Metric of Erythropoiesis-Stimulating Agent Response in Hemodialysis PatientsCalvin J Meaney, Spinel Karas, Ben Robinson, et al.
Antimicrobial Agents and Chemotherapy|July 15, 2009
Pharmacodynamics of vancomycin at simulated epithelial lining fluid concentrations against methicillin-resistant Staphylococcus aureus (MRSA): implications for dosing in MRSA pneumoniaYoriko Harigaya, Jürgen B Bulitta, Alan Forrest, et al.
Current Pharmaceutical Biotechnology|May 11, 2011
Relevance of pharmacokinetic and pharmacodynamic modeling to clinical care of critically ill patientsJurgen B Bulitta, Cornelia B Landersdorfer, Alan Forrest, et al.
Biopharmaceutics & Drug Disposition|November 29, 2007
Pharmacokinetic interaction between efavirenz and dual protease inhibitors in healthy volunteersQing Ma, Alan Forrest, Susan L Rosenkranz, et al.
The Journal of Antimicrobial Chemotherapy|November 29, 2007
Microbiological effects of prior vancomycin use in patients with methicillin-resistant Staphylococcus aureus bacteraemiaPamela A Moise, Davida S Smyth, Nadia El-Fawal, et al.
Antimicrobial Agents and Chemotherapy|August 1, 2018
Population Pharmacokinetic Analyses for Ertapenem in Subjects with a Wide Range of Body SizesElizabeth A Lakota, Cornelia B Landersdorfer, Li Zhang, et al.
Expert Opinion on Drug Metabolism & Toxicology|May 7, 2013
Considering CYP1A2 phenotype and genotype for optimizing the dose of olanzapine in the management of schizophreniaVidya Perera, Annette S Gross, Thomas M Polasek, et al.
Scientific Reports|March 31, 2017
Untargeted metabolomics analysis reveals key pathways responsible for the synergistic killing of colistin and doripenem combination against Acinetobacter baumanniiMohd Hafidz Mahamad Maifiah, Darren J Creek, Roger L Nation, et al.
Pageof 18